# Eledon Pharmaceuticals, Inc.: overview ELDN · Nasdaq · CIK 1404281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/eldn.md) · [Financials](/companies/eldn/financials.md) · [Filings](/companies/eldn/filings.md) · [Insiders](/companies/eldn/insiders.md) Latest reported revenue: [$0](/filings/0001193125-17-156191.md) for Q1 FY2017, three months to 2017-03-31, from the 10-Q filed May 3, 2017 (XBRL us-gaap:SalesRevenueGoodsNet, accession 0001193125-17-156191). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.28)](/filings/0001193125-25-283275.md) | not reported | [(0.08)](/filings/0001193125-26-221702.md) | [(0.13)](/filings/0001193125-26-349314.md) | [(0.21)](/filings/0001193125-25-283275.md) | not reported | [(0.33)](/filings/0001193125-26-221702.md) | [(0.27)](/filings/0001193125-26-349314.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.33)](/filings/0000950170-23-011011.md) | [(6.16)](/filings/0000950170-24-098575.md) | [(4.73)](/filings/0000950170-25-042754.md) | [(0.66)](/filings/0001193125-26-116164.md) | [(0.52)](/filings/0001193125-26-116164.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eldn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $24.8m | 6,293,282 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $20.2m | 5,123,842 | | Added +741,597 | | [Defilade Capital Management, L.P.](/funds/2088557.md) | 2026-06-30 | $13.9m | 3,525,338 | | Reduced −38,789 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.5m | 3,417,223 | | Added +124,089 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $9.9m | 2,510,308 | | Added +2,140,218 | | [Ensign Peak Advisors, Inc](/funds/1454984.md) | 2026-06-30 | $8.3m | 2,101,224 | | Reduced −363,695 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $7.7m | 1,956,601 | | Added +164,818 | | [Catalio Capital Management, LP](/funds/1958125.md) | 2026-06-30 | $6.7m | 1,695,071 | | Added +55,255 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $6.4m | 1,621,969 | | Added +467,298 | | [Zimmer Partners, LP](/funds/1565854.md) | 2026-06-30 | $6.3m | 1,596,599 | | Reduced −278,401 | ## Recent filings [All 600 filings](/companies/eldn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 16:30 ET | [10-Q](/filings/0001193125-26-349314.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349314 | | 2026-08-13 | 16:08 ET | [8-K](/filings/0001193125-26-349170.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349170 | | 2026-06-22 | 17:00 ET | [8-K](/filings/0001193125-26-277653.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277653 | | 2026-05-13 | 16:20 ET | [10-Q](/filings/0001193125-26-221702.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221702 | | 2026-05-13 | 16:15 ET | [8-K](/filings/0001193125-26-221658.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221658 | | 2026-04-30 | 16:57 ET | [DEF 14A](/filings/0001193125-26-197732.md) | Proxy statement, period 2026-06-18 | 0001193125-26-197732 | | 2026-03-19 | 17:05 ET | [10-K](/filings/0001193125-26-116164.md) | Annual report, period 2025-12-31 | 0001193125-26-116164 | | 2026-03-19 | 17:02 ET | [8-K](/filings/0001193125-26-116154.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-116154 | | 2026-01-02 | 16:30 ET | [8-K](/filings/0001193125-26-000968.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-000968 | | 2025-11-14 | 17:11 ET | [8-K](/filings/0001193125-25-283294.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-283294 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-116164.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1404281 - Tickers: ELDN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:26 ET. No prices; not investment advice.